Scarica l'app Stockscreener
542.71
0.01%
0.06
Dopo l'orario di chiusura:
542.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IDXX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$542.65
Aprire:
$541.48
Volume 24 ore:
380.13K
Relative Volume:
0.50
Capitalizzazione di mercato:
$42.30B
Reddito:
$3.93B
Utile/perdita netta:
$894.97M
Rapporto P/E:
50.16
EPS:
10.82
Flusso di cassa netto:
$837.70M
1 W Prestazione:
+2.32%
1M Prestazione:
+5.42%
6M Prestazione:
+32.74%
1 anno Prestazione:
+13.72%
Intervallo 1D:
$538.70
$546.00
Intervallo di 1 settimana:
$524.65
$546.39
Portata 52W:
$356.14
$546.39
Idexx Laboratories Inc Stock (IDXX) Company Profile
Nome
Idexx Laboratories Inc
Settore
Industria
Telefono
(207) 556-0300
Indirizzo
ONE IDEXX DRIVE, WESTBROOK, ME
Confronta IDXX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
542.71 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
TMO
Thermo Fisher Scientific Inc
|
427.76 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
202.50 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
A
Agilent Technologies Inc
|
120.66 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
164.65 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Iniziato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | BTIG Research | Buy |
| 2024-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Iniziato | Exane BNP Paribas | Outperform |
| 2023-12-04 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Downgrade | Stifel | Buy → Hold |
| 2022-07-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-07-12 | Iniziato | Piper Sandler | Overweight |
| 2022-05-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-08 | Iniziato | Atlantic Equities | Overweight |
| 2021-11-18 | Iniziato | Morgan Stanley | Overweight |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-17 | Iniziato | Barclays | Overweight |
| 2019-09-09 | Iniziato | Goldman | Neutral |
| 2019-05-23 | Iniziato | Guggenheim | Buy |
| 2018-11-02 | Reiterato | BofA/Merrill | Buy |
| 2018-05-07 | Reiterato | Stifel | Buy |
| 2018-01-16 | Iniziato | Piper Jaffray | Overweight |
| 2017-08-23 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Aggiornamento | CL King | Neutral → Buy |
| 2017-02-03 | Downgrade | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Ripresa | BofA/Merrill | Neutral |
| 2016-08-16 | Reiterato | Stifel | Buy |
| 2016-08-03 | Aggiornamento | Northcoast | Sell → Neutral |
| 2016-07-20 | Reiterato | Canaccord Genuity | Buy |
| 2016-04-19 | Reiterato | Canaccord Genuity | Buy |
| 2016-04-01 | Iniziato | CL King | Neutral |
| 2016-03-21 | Reiterato | Stifel | Buy |
| 2016-02-04 | Iniziato | Credit Suisse | Outperform |
| 2015-10-29 | Reiterato | Stifel | Buy |
| 2015-08-28 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Reiterato | Stifel | Buy |
| 2015-07-23 | Reiterato | Canaccord Genuity | Buy |
Mostra tutto
Idexx Laboratories Inc Borsa (IDXX) Ultime notizie
IDEXX Laboratories (IDXX) Price Target Hiked to $580 at Leerink Partners - Insider Monkey
12 Best Healthcare Stocks to Buy Now - Insider Monkey
IDEXX Laboratories Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
IDEXX Laboratories (IDXX) Sees Price Target Raised by Leerink Pa - GuruFocus
Three Lawmakers Bought This Biotech Stock Before Supporting A Bill That Could Boost Its Value: It's Now Up 44% - Benzinga
Is IDEXX Laboratories Stock Outperforming The Dow? - Barchart.com
Is IDEXX Laboratories Stock Outperforming the Dow? - The Globe and Mail
Leerink Partners Adjusts IDEXX Laboratories Price Target to $580 From $515 - MarketScreener
Kalkine : IDEXX Laboratories Performance Within S&P 500 Index Framework - Kalkine Media
IDEXX Labs $IDXX Sees Surge in Political Buys: 3 Politicians on Agriculture Committees Invest – Crypto Market Eyes Regulatory Impact - Blockchain News
IDEXX Catalyst Cortisol Rapid Canine Dx - Precedence Research
Amazon Delivery Robots Could Haunt Your Front Porch - Yahoo! Autos
Jim Cramer on IDEXX Laboratories, Inc. (IDXX): “I Just Can’t Get My Arms Around It” - MSN
Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders - StreetInsider
IDEXX Unveils Game-Changing Dog Disease Test: Breakthrough for Detecting Life-Threatening Addison's Disease - Stock Titan
IDEXX Laboratories (IDXX) Stock Analysis: A Look at Its Robust 59.33% ROE Amidst Market Challenges - DirectorsTalk Interviews
Jim Cramer’s Thoughts on These 10 Stocks - Insider Monkey
IDEXX Laboratories (NASDAQ:IDXX) Stock Rating Lowered by Wall Street Zen - Defense World
Companion Animal Diagnostics Market Is Booming WorldwideIDEXX Laboratories, Heska Corporation - openPR.com
Transcript : IDEXX Laboratories, Inc. Presents at Stifel Jaws & Paws Conference 2025, May-28-2025 10 - marketscreener.com
IDEXX Laboratories To Present At Stifel Jaws & Paws Conference; Webcast At 10:55 AM ET - Nasdaq
IDEXX Laboratories Stock: Analyst Estimates & Ratings - MSN
IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - simplywall.st
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
IDEXX Lab jumps after Q1 beat and guidance raise - MSN
$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today - Benzinga
IDEXX Laboratories (NASDAQ:IDXX) Given New $510.00 Price Target at Stifel Nicolaus - Defense World
IDEXX Laboratories (IDXX) Target Price Raised by Stifel to $510 | IDXX Stock News - GuruFocus
If You Invested $1000 in Idexx Laboratories a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Idexx Laboratories (IDXX) Price Target Increased by Stifel Analy - GuruFocus
Stifel Adjusts Price Target on IDEXX Laboratories to $510 From $460, Maintains Hold Rating - marketscreener.com
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil - TradingView
IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits (NASDAQ:IDXX) - Seeking Alpha
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Director Cashes In: Idexx Laboratories Stock Sale Revealed - TipRanks
IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day | IDXX Stock News - GuruFocus
IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day - Business Wire
BNP Paribas Exane Adjusts Price Target on IDEXX Laboratories to $577 From $566, Maintains Outperform Rating - marketscreener.com
IDEXX Laboratories (NASDAQ:IDXX) Upgraded at StockNews.com - Defense World
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable - simplywall.st
Idexx outlines 2025 growth with 6-9% organic revenue target amid innovation launches - MSN
IDEXX Laboratories (IDXX) Announces Key Amendments to Corporate Structure - GuruFocus
IDEXX Laboratories Updates Corporate Governance Structure - TipRanks
Here’s Why Baron Focused Growth Fund Invested in IDEXX Laboratories (IDXX) - Insider Monkey
IDEXX Laboratories (NASDAQ:IDXX) Price Target Raised to $558.00 at Morgan Stanley - Defense World
Rep. April McClain Delaney Buys IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock - Defense World
IDEXX Laboratories (IDXX) Target Price Raised by Morgan Stanley | IDXX Stock News - GuruFocus
Idexx Laboratories Inc Azioni (IDXX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Idexx Laboratories Inc Azioni (IDXX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SZOSTAK M ANNE | Director |
May 21 '25 |
Option Exercise |
160.28 |
1,046 |
167,653 |
1,308 |
| SZOSTAK M ANNE | Director |
May 21 '25 |
Sale |
512.34 |
1,260 |
645,545 |
1,801 |
| SZOSTAK M ANNE | Director |
May 21 '25 |
Sale |
513.74 |
1,046 |
537,372 |
262 |
0.17%
1.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):